Start Free Trial
Pricing
Log In
Log In
Upgrade browser for full Crunchbase experience. You're accessing Crunchbase in a browser that is no longer supported.
Learn More
Alcon Logo
Alcon Growth Score
52
CB Rank
90610
Heat Score
71
Alcon specializes in developing and manufacturing innovative medicines and devices to serve the cycle of eye care.
Acquired by
Novartis Logo
Novartis
Founded
obfuscation
Delisted Vernier, Geneve, Switzerland10001+ www.alcon.com
Health Care
Manufacturing
Medical Device
Overview

Alcon
Growth Score
52
Heat Score
71

Growth Score52
-10 pts
in past quarter
Heat Score 71
9 pts
in past quarter

Company Performance Metrics

Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Learn More >
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
+3 more milestones
See more interactive data and historical milestones on desktop for the best experience

About Alcon

CB Rank
90610
Alcon specializes in developing and manufacturing innovative medicines and devices to serve the cycle of eye care.
Acquired by
Novartis Logo
Novartis
Founded
obfuscation
Delisted Vernier, Geneve, Switzerland10001+ www.alcon.com
Health Care
Manufacturing
Medical Device

Key People

Details

Legal Name Alcon Vision LLC
Also Known As Alcon Laboratories
Operating Status Active
Number of Exits 
obfuscation
Stock Symbol  NYSE:ALC
Company Type For Profit
Founders  Robert Alexander, William Conner
About the Company
Alcon is a medical device manufacturing company that develops and manufactures innovative medicines and devices to serve the full life cycle of eye care needs. It specializes in the fields of ophthalmology pharmaceuticals and medical devices, eye care, and eye health. The company was founded in 1945 and headquartered in Geneva, Switzerland.
Phone Number +41 62 205 77 00
Contact Email investor.relations@alcon.com
Predictions & Insights

Growth Insight

See this Growth Insight
Alcon is
Lorem
 to be growing
Top Contributing Factors
Financial Growth

Products & Services

UNITY Vision Systems (UNITY VCS and UNITY CS)
Surgical platforms designed to support vitreoretinal and cataract surgeries by managing fluidics and maintaining anterior chamber stability.
AcrySof Intraocular Lenses (IOLs)
Implantable lenses used during cataract surgery to replace the eye's natural lens and correct refractive errors.

Unlock More with Crunchbase Pro
  • Full access to financial & funding data on unlimited profiles
  • Export up to 2k results/month for analysis
  • Track market signals on competitors, products, and R&D
  • Preview private company insights and predictions
Financials

Investments

Number of Investments 3
Number of Exits 
obfuscation
Number of Acquisitions 15
See investment data for this company, with details on deal size, industry, stage, and more.
Announced Date  
Organization Name  
Lead Investor  
Funding Round  
Money Raised  
obfuscation
Ocumension Therapeutics Logo
Ocumension Therapeutics
Yes
Post-IPO Equity - Ocumension Therapeutics Logo
Post-IPO Equity - Ocumension Therapeutics
obfuscation
obfuscation
Ocumension Therapeutics Logo
Ocumension Therapeutics
Yes
Post-IPO Equity - Ocumension Therapeutics Logo
Post-IPO Equity - Ocumension Therapeutics
obfuscation
obfuscation
Ocumension Therapeutics Logo
Ocumension Therapeutics
Yes
Post-IPO Equity - Ocumension Therapeutics Logo
Post-IPO Equity - Ocumension Therapeutics
obfuscation
obfuscation
Ocumension Therapeutics Logo
Ocumension Therapeutics
Yes
Post-IPO Equity - Ocumension Therapeutics Logo
Post-IPO Equity - Ocumension Therapeutics
obfuscation
obfuscation
Ocumension Therapeutics Logo
Ocumension Therapeutics
Yes
Post-IPO Equity - Ocumension Therapeutics Logo
Post-IPO Equity - Ocumension Therapeutics
obfuscation

Investment Breakdown

Number of Investments 3
Number of Exits 
obfuscation
Number of Acquisitions 15
See investment data for this company, with details on deal size, industry, stage, and more.
Announced Date  
Organization Name  
Lead Investor  
Funding Round  
Money Raised  
obfuscation
Ocumension Therapeutics Logo
Ocumension Therapeutics
Yes
Post-IPO Equity - Ocumension Therapeutics Logo
Post-IPO Equity - Ocumension Therapeutics
obfuscation
obfuscation
Ocumension Therapeutics Logo
Ocumension Therapeutics
Yes
Post-IPO Equity - Ocumension Therapeutics Logo
Post-IPO Equity - Ocumension Therapeutics
obfuscation
obfuscation
Ocumension Therapeutics Logo
Ocumension Therapeutics
Yes
Post-IPO Equity - Ocumension Therapeutics Logo
Post-IPO Equity - Ocumension Therapeutics
obfuscation
obfuscation
Ocumension Therapeutics Logo
Ocumension Therapeutics
Yes
Post-IPO Equity - Ocumension Therapeutics Logo
Post-IPO Equity - Ocumension Therapeutics
obfuscation
obfuscation
Ocumension Therapeutics Logo
Ocumension Therapeutics
Yes
Post-IPO Equity - Ocumension Therapeutics Logo
Post-IPO Equity - Ocumension Therapeutics
obfuscation

M&A Details

Alcon merged with Novartis for
obfuscation
on
obfuscation
. This deal was done in Cash.
Transaction Name 
Alcon acquired by Novartis Logo
Alcon acquired by Novartis
Acquired by 
Novartis Logo
Novartis
Announced Date 
obfuscation
Price 
obfuscation
Market Intelligence
People
View Profiles & Contacts
Headcount 10001+ Employee Profiles 24 Board Members and Advisors 7 Contacts 9,866

Employee Profiles

Board Members and Advisors

News

News and Press

News•May 29, 2026
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
News•May 29, 2026
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
News•May 20, 2026
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
News•May 11, 2026
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
Access a complete feed of recent news and press, from product launches to leadership changes.
Technology
View Tech Report

Monthly Web Visits

454,123
266.77%
 in past month

IT Spend

$610.8MThis year, Alcon is projected to spend $610.8M on IT, according to Aberdeen.

Interest Signals

TopicSurge Score
Thought Leadership Logo
Thought Leadership
100
Data Loss Prevention Logo
Data Loss Prevention
100
Gigabit Networking Logo
Gigabit Networking
100

Actively Used Products

26Alcon uses 26 technology products and services including HTML5, Google Attribution, and  F5 NGINX, according to G2 Stack.

Active Website Tech Count

95Alcon is actively using 95 technologies for its website, according to BuiltWith. These include IPhone / Mobile Compatible, Viewport Meta, and  HSTS.

Total IP

4,576The intellectual property of Alcon includes 3,096 registered patents primarily in the 'Medical Or Veterinary Science; Hygiene' category, according to IPqwery. Additionally, Alcon has registered 1,480 trademarks with the most popular class being 'Medical apparatus and instruments', according to IPqwery.
Sub-Organizations

Sub-Organizations

Number of Sub-Orgs 1
Which industries do these Sub-Organization operate in?
Alcon Pharmaceuticals Logo
Alcon PharmaceuticalsSubsidiary
Frequently Asked Questions

Where is Alcon's headquarters? Alcon is located in Vernier, Geneve, Switzerland.Who are Alcon's competitors? Alternatives and possible competitors to Alcon may include BVI Medical, Vision Direct, and  Omisan Farmaceutici.
Who We Are
What We Do
Helpful Links
AI Content may contain mistakes and is not legal, financial or investment advice. Learn more.
Terms of Service | Privacy Policy | Sitemap | © 2026 Crunchbase Inc. All Rights Reserved.
(5eb04bf 1)
|